Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Mesothelioma: Current And Future Perspectives.

Konstantinos Porpodis, P. Zarogoulidis, E. Boutsikou, A. Papaioannou, Nikolaos Machairiotis, K. Tsakiridis, N. Katsikogiannis, B. Zaric, B. Perin, H. Huang, Ioanna Kougioumtzi, Dionysios Spyratos, K. Zarogoulidis
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Mesothelioma still remains an occupational related cancer with severe outcome. It is usually diagnosed at advanced stage since it does not demonstrate early symptoms. Several efforts have been made towards removing all materials inducing mesothelioma in the work setting and new work protection measures have been applied. Although we have new targeted treatments and radical surgery as arrows in the quiver, the type of mesothelioma and early diagnosis still remain the best treatment approach. Novel treatment modalities have been explored and several others are already on the way. In the current review we will present current data for mesothelioma and future perspectives.
This paper references
10.3390/ijms140714771
Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy
S. Sethi (2013)
10.1007/s11864-008-0071-3
Systemic Treatments for Mesothelioma: Standard and Novel
H. Kindler (2008)
10.1007/s12094-013-1015-3
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens
E. Habib (2013)
10.1510/icvts.2010.251488
A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS).
T. Treasure (2011)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1159/000216501
Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.
H. Henss (1988)
10.1093/ANNHYG/11.4.283
Asbestos bodies and mesothelioma.
J. Stumphius (1968)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1016/S0169-5002(00)00192-6
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
B. Castagneto (2001)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
10.1038/modpathol.3800534
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
10.1038/sj.onc.1210515
Eighth International Mesothelioma Interest Group
M. Carbone (2007)
resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma
S Ting (2013)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1093/OCCMED/KQI034
Mesothelioma mortality in Great Britain from 1968 to 2001.
D. McElvenny (2005)
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
10.1097/JTO.0b013e31828353d7
Surgery in mesothelioma--where do we go after MARS?
B. Hiddinga (2013)
Phase II study of asparagine-glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma
V Gregorc (2010)
10.1097/JTO.0b013e31823f45c1
Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
D. Pinato (2012)
10.1177/107327480601300402
Malignant pleural mesothelioma: a comprehensive review.
R. Ismail-Khan (2006)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.5858/arpa.2012-0214-OA
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/J.EJCA.2007.09.018
Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
A. Marinaccio (2007)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1177/1947601911412375
Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth.
Masaki Nasu (2011)
10.1097/JTO.0b013e31822a3740
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
S. Kao (2011)
10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
10.1371/journal.pone.0018232
Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
L. Santarelli (2011)
10.1016/j.bcp.2011.07.073
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
F. Barbieri (2011)
10.1016/S0959-8049(02)00668-8
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
P. Baas (2003)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1016/j.ctrv.2012.11.004
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
C. Pinto (2013)
10.1186/1756-0500-5-482
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1111/j.1759-7714.2010.00001.x
Management of malignant pleural mesothelioma
P. Hürmüz (2010)
[Guidelines for pathologic diagnosis of malignant mesothelioma--2012 update of the consensus statement from the International Mesothelioma Interest Group].
Riping Chen (2015)
A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas.
J. Testa (1998)
10.1007/s00280-013-2216-8
Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
Maged P. Mansour (2013)
10.1378/CHEST.121.6.1921
Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.
I. Monnet (2002)
Malignant pleural mesothelioma cancer diagnosis and therapy
Porpodis (2013)
10.1016/j.cllc.2013.04.013
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
S. Ting (2013)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1517/17425255.2013.804065
An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment
O. Caffo (2013)
10.1158/1078-0432.CCR-12-3202
Extracellular Signal–Regulated Kinase 5: A Potential Therapeutic Target for Malignant Mesotheliomas
A. Shukla (2013)
10.1053/j.semtcvs.2009.07.002
Recent advances in mesothelioma staging.
W. Richards (2009)
Malignant mesothelioma in Australia
A. Musk (2006)
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma . European Organization for research and treatment of
JP vanMeerbeeck
10.3978/j.issn.2072-1439.2013.03.03
The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.
T. Mori (2013)
10.1038/sj.bjc.6604421
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
J. Sørensen (2008)
10.1179/oeh.2007.13.4.398
Incidence and Descriptive Epidemiology of Mesothelioma in the United States, 1999–2002
Theodore C. Larson (2007)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1038/bjc.2011.400
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
E. Giovannetti (2011)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/j.rmed.2010.10.010
Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
N. Hirayama (2011)
Ad-IFNγ Induces Antiproliferative and Antitumoral Responses in Malignant Mesothelioma
Florence Gattacceca (2002)
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
N. Nasreen (2012)
10.1158/1078-0432.CCR-05-1191
Inhibition of the Met Receptor in Mesothelioma
T. Mukohara (2005)
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia
AP Chahinian (1993)
10.1007/s00280-012-1965-0
A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma
Zarah Glad Zimling (2012)
10.1136/jclinpath-2012-201020
CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma
D. Pinato (2012)
10.1158/1078-0432.CCR-11-0937
Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
D. Rischin (2011)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1097/JTO.0b013e3181ae25bf
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
10.1016/J.LUNGCAN.2006.09.023
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
C. Obasaju (2007)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1517/14728210903074563
Malignant pleural mesothelioma: current treatments and emerging drugs
C. Belli (2009)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1016/j.lungcan.2013.05.014
The role of epigenetics in malignant pleural mesothelioma.
Fabian Vandermeers (2013)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1016/S1470-2045(12)70037-2
Optimising therapy for EGFR-addicted NSCLC: just the start.
Ramaswamy Govindan (2012)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1200/JCO.2009.27.3649
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
V. Gregorc (2010)
10.1371/journal.pone.0058051
Preclinical Demonstration of Synergistic Active Nutrients/Drug (AND) Combination as a Potential Treatment for Malignant Pleural Mesothelioma
Viviana Volta (2013)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.2217/pgs.13.79
Personalized medicine in oncology: where have we come from and where are we going?
F. André (2013)
10.1097/JTO.0b013e31818b174d
Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study
G. Hillerdal (2008)
10.1097/JTO.0b013e3181d2f008
Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma
A. Yasumitsu (2010)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1038/bjc.2012.44
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
Ó. Arrieta (2012)
10.1200/JCO.20.1.274
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
S. Mikulski (2002)
cooperative group
EE Habib (1999)
Mesothelioma mortality in Great Britain
DM McElvenny (1968)
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for research and treatment of cancer lung cancer cooperative group. Cancer 1999;85:2577-82
JP van Meerbeeck (1999)
10.1016/J.JTCVS.2003.08.034
Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.
Robert J Kruklitis (2004)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
[Possible use of microRNAs as biomarkers for monitoring of workers exposed to asbestos].
Elena Sturchio (2012)
10.1007/s11864-011-0154-4
Surgical Treatment of Malignant Pleural Mesothelioma
A. Kaufman (2011)
Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma.
Florence Gattacceca (2002)
10.1016/j.lungcan.2013.05.006
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.3816/CLC.2006.N.003
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
L. Krug (2006)
10.1179/oeh.2003.9.3.249
Asbestos-related Morbidity in India
T. Joshi (2003)
10.1016/j.ejca.2013.05.008
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
M. O'Brien (2013)
10.1378/CHEST.113.1_SUPPLEMENT.61S
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)
10.1258/jrsm.2010.100345
A systematic review of lung-sparing extirpative surgery for pleural mesothelioma
Elaine S Teh (2011)
10.1378/CHEST.123.2.551
Surgical treatment of malignant pleural mesothelioma: a review.
S. van Ruth (2003)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1164/rccm.200807-1125OC
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
10.1593/NEO.04271
Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.
Z. Liu (2004)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.3.CO;2-J
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck (1999)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Task Force ( FONICAP ) Phase II study
AP Chahinian (1991)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
[Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update].
E. Porret (2007)
Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.
G. Gálffy (1999)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1016/S0169-5002(00)00166-5
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
10.1097/00002371-199809000-00007
Intralesional Cytokine Therapy in Cancer: A Pilot Study of GM‐CSF Infusion in Mesothelioma
J. A. Davidson (1998)
10.1186/1471-2407-13-205
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma
C. Tabata (2012)
10.1097/JTO.0b013e3182572e83
Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma
M. Kirschner (2012)
10.1002/AJIM.10047
Malignant mesothelioma in Australia, 1945-2000.
J. Leigh (2002)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1158/1078-0432.CCR-10-2245
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
S. Kao (2010)
10.1017/erm.2012.6
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
10.1016/S0140-6736(00)04013-7
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Iman Roushdy-Hammady (2001)
10.1186/1477-7819-8-88
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
J. Foster (2010)
10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study
A. Ardizzoni (1991)



This paper is referenced by
10.1016/j.ncrna.2018.08.001
Relations between approved platinum drugs and non-coding RNAs in mesothelioma
Bernhard Biersack (2018)
10.1186/s12885-015-1881-x
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
Christine Raynaud (2015)
10.1186/s40064-016-1893-2
An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol
Y. Tada (2016)
10.1042/BST20150252
The role of the HGF/Met axis in mesothelioma.
Thivyan Thayaparan (2016)
10.3389/fgene.2017.00070
Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
Jelena Kresoja-Rakic (2017)
10.1186/1746-1596-8-195
Primary solitary fibrous tumors of liver: a case report and literature review
Qiang Liu (2013)
10.5539/CCO.V3N1P16
A Retrospective Study of Palliative Cisplatin-Based Doublet Chemotherapy for Malignant Pleural Mesothelioma
S. Sørensen (2014)
10.7150/oncm.20980
Malignant Pleura Mesothelioma: Clinical Perspectives
Konstantinos Grapatsas (2017)
10.21037/jtd.2017.10.74
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
Luca Ampollini (2018)
10.1080/21678707.2017.1325358
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma
Emyr Bakker (2017)
10.1007/978-3-319-30741-1_13
Molecular Biomarkers in Body Fluid Cytology
Rachel Conrad (2016)
10.7150/jca.48691
Lung cancer biopsies: Comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA
P. Zarogoulidis (2020)
10.7314/APJCP.2014.15.20.8843
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
Seyda Gunduz (2014)
10.1371/journal.pone.0150338
Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma
Michael Tayao (2016)
10.1186/s40064-015-1123-3
A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
Y. Tada (2015)
10.7150/jca.16390
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy
R. F. Walter (2016)
10.18632/oncotarget.9686
Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis
Luigina Micolucci (2016)
10.1186/s12931-017-0546-5
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives
L. Cortes-Dericks (2017)
10.1080/0284186X.2018.1532599
Malignant pleural mesothelioma in Finland: regional and gender variation
Sanna Laaksonen (2019)
10.1016/j.crad.2019.12.001
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.
S. Sinha (2020)
10.24875/j.gamo.m17000064
Advanced malignant pleural mesothelioma: Experience in 42 patients
V. Robles-Pérez (2017)
10.1517/14712598.2015.1116515
Tremelimumab for the treatment of malignant mesothelioma
A. Guazzelli (2015)
10.2147/OV.S66091
Oncolytic virotherapy for human malignant mesothelioma: recent advances
Nicolas Boisgerault (2015)
10.1007/s00262-016-1844-3
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
S. Roncella (2016)
10.1186/s13287-016-0282-7
Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines
L. Cortes-Dericks (2016)
10.1007/s00270-017-1583-7
A Single-Institution Experience in Percutaneous Image-Guided Biopsy of Malignant Pleural Mesothelioma
B. Welch (2017)
10.1016/j.fob.2015.07.005
A novel link between FMR gene and the JNK pathway provides clues to possible role in malignant pleural mesothelioma
A. Srivastava (2015)
Semantic Scholar Logo Some data provided by SemanticScholar